Clay B. Siegll is a famous individual in the world. He is the CEO and president of a biotechnology company known as Seattle Genetics. Clay founded the biotechnology company in 1998, and he is also the chairman of the board of directors. Siegall is a trained scientist, and he specializes in cancer therapies. Siegall started the firm on the foundation of rigorous research, drug development practices, scientific innovation and passion for helping people who have cancer. Under his guidance, Seattle Genetics has been able to achieve its goals, and it is one of the pioneers in the development of antibody therapies for treating cancer.
Before Seattle Genetics in 1998, the successful biotechnologist was working at the National Cancer Institute. He was also working at the National Institute of Health for several years. In the year 1991, Clay was appointed to join Bristol-Myers Squibb Pharmaceutical Research Institute. He worked in this institution for six years, bringing some significant changes. Today, he is a board member of a company known as BioPhamaceuticals. The agency is privately held, and it has also transformed the lives of many people.
Clay Siegall has made several accomplishments while working as the Chief Executive Officer of Seattle Genetics. First of all, the company has managed to develop several antibody therapies to meet the medical needs of the cancer patients in the world.
Clay Siegall spoke during the fifth annual CHI Antibody Drug Conjugates Conference that was held recently, and he confirmed that so far Adcetris has successfully managed to treat over fifteen thousand cases of lymphoma. The biotechnologist believes that the drug will continue to cure patients in the future and giving hope to cancer patients.
Apart from Adcetris, the company, under the leadership of Clay Siegall is in its last stages of advancing seven clinical programs. According to Clay, the firm will be introducing new programs to treat different types of cancer. Seattle Genetics has announced its plans to increase its employees to ensure that all its programs are completed in time.
The Bothell, Washington based drug firm Seattle Genetics has unveiled an ambitious plan to expand its drug business and increase the size of its workforce. According to an excerpt published in theBizjournals.com, the fast growing cancer drug maker plans to widen the reach of its only commercialized cancer drug, Adcetris and hire 100 new workers. The company CEO, Clay Siegall told Bizjournals that there are ongoing clinical trials to test Adcetris on the treatment of various types of lymphomas.
In 2015, the company made a staggering $226 million from sales of the drug in the US and Canada. Sales in the two North American countries are expected to rise to about $265 million in 2016 as the company looks to ramp up its overseas sales through its marketing partner, Takeda Pharmaceutical. Seattle Genetics has already initiated a capital intensive phase 3 trials to check the viability of treating newly diagnosed Hodgkin lymphoma and other related conditions using Adcetris.
The company also hopes to unveil 12 new drugs it has been developing on the sidelines of Adcentric. The drugs on trials include 33A for treating acute myeloid leukemia and drugs for treating and managing bladder and breast cancer. Seattle Genetics will also hire 100 new workers in its US office and an additional 20 to work in its Switzerland outpost. The move will bring the number of employees working for the company to close to 1000.
About Clay Siegall
Dr. Clay Siegall is the CEO and Co-Founder of Seattle Genetics biotech company. According to Siegall’s LinkedIn account, the firm was established in 1998 on a strong foundation of continued research, scientific innovation, passion to help patients and steady drug development pathway. Through Siegall’s stellar leadership, Seattle Genetics has become a leader in the development of antibody-drug conjugates (ADC)drugs.
The company has strategic working licenses with a number of companies including Pfizer and GlaxoSmithKline to promote the ADC technology. Siegall holds a Ph.D. in Genetics from George Washington University and a BSc in Zoology from University of Maryland.